Form 4: Viking Global Investors Sells INBX Shares

Viking Global Investors LP and affiliated entities reported the sale of 359,000 shares of Inhibrx Biosciences, Inc. common stock for $32.25 per share.

Summary

• Viking Global Investors LP and several affiliated entities, including Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, and individuals Ole Andreas Halvorsen, David C. Ott, and Rose S. Shabet (collectively, 'Reporting Persons'), filed a Form 4.
• The filing reports the disposition of Inhibrx Biosciences, Inc. (INBX) common stock by the Reporting Persons, who are identified as a 10% owner.
• A total of 359,000 shares of common stock were sold across three separate transactions on October 7, 2025.
• All shares were sold at a uniform price of $32.25 per share.
• Following these transactions, the Reporting Persons indirectly beneficially own a total of 1,437,705 shares of Inhibrx Biosciences, Inc. common stock.

Sentiment

Score: 3

Explanation: The sale of a significant number of shares by a 10% owner, Viking Global Investors LP, is generally viewed as a negative signal, indicating a potential reduction in confidence or a strategic divestment. This could put downward pressure on the stock price.

Negatives

• A significant 10% owner, Viking Global Investors LP and its affiliates, disposed of a substantial block of 359,000 shares of Inhibrx Biosciences, Inc. common stock.
• The sale occurred at a price of $32.25 per share, which could be interpreted as a strategic divestment or a lack of conviction at this valuation by a major institutional investor.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Inhibrx Biosciences, Inc.'s future performance or strategic direction.

Industry Context

This transaction represents an institutional investor's decision to reduce its stake in a biotechnology company. Such sales by significant shareholders can sometimes be interpreted by the market as a signal regarding the investor's view on the company's valuation or future prospects within the competitive biotech landscape.

Stakeholder Impact

• Shareholders: May interpret the sale by a major institutional investor as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

The sale of a substantial block of shares by a 10% owner, Viking Global Investors LP, and its affiliates, typically signals a lack of conviction or a strategic exit from the position. This action by a sophisticated institutional investor could precede further declines or indicate that the current valuation is considered high. While not a definitive indicator, such a large insider sale warrants caution and suggests a 'sell' recommendation for investors considering the stock, or at least a 'hold' for those already invested, pending further positive developments.

Keywords

Inhibrx Biosciences, INBX, Viking Global Investors, Insider Trading, Form 4, Stock Sale, Beneficial Ownership, Institutional Investor